Literature DB >> 24018470

Pegylated liposomal doxorubicin: a guide to its use in various malignancies.

Katherine A Lyseng-Williamson1, Sean T Duggan, Gillian M Keating.   

Abstract

Pegylated liposomal doxorubicin (Caelyx(®) [EU], Doxil(®) [USA]) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24018470     DOI： 10.1007/s40259-013-0070-1

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   5.807


  14 in total

1.  Milk derived colloid as a novel drug delivery carrier for breast cancer.

Authors:  Masamichi Hayashi; Nissim Silanikove; Xiaofei Chang; Rajani Ravi; Vui Pham; Gilson Baia; Keren Paz; Mariana Brait; Wayne M Koch; David Sidransky
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 2.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

3.  Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy.

Authors:  Danny Maples; Kevin McLean; Kaustuv Sahoo; Ryan Newhardt; Perumal Venkatesan; Bradford Wood; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2015-07-17       Impact factor: 3.914

Review 4.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

5.  Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.

Authors:  Xi-Zhi Wen; Qiu-Zhong Pan; Bu-Shu Xu; Wei Xiao; De-Sheng Weng; Jing-Jing Zhao; Hai-Rong Xu; Zhen Huang; Xiao-Hui Niu; Xing Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-13       Impact factor: 3.288

6.  Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.

Authors:  Shigeru Kusumoto; Kazutaka Sunami; Mitsuo Inagaki; Shinsuke Iida
Journal:  Int J Hematol       Date:  2015-03-07       Impact factor: 2.319

Review 7.  Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology.

Authors:  Andrew M Hersh; Safwan Alomari; Betty M Tyler
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

8.  Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

Authors:  Talia Golan; Tal Grenader; Patricia Ohana; Yasmine Amitay; Hilary Shmeeda; Ninh M La-Beck; Esther Tahover; Raanan Berger; Alberto A Gabizon
Journal:  Cancer Med       Date:  2015-07-14       Impact factor: 4.452

9.  Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells.

Authors:  Shaoling Wu; Xindong Zhao; Zhongguang Cui; Chunting Zhao; Yuzhen Wang; Li Du; Yanhui Li
Journal:  Int J Nanomedicine       Date:  2014-03-14

10.  Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

Authors:  Jan Kroon; Jeroen T Buijs; Geertje van der Horst; Henry Cheung; Maaike van der Mark; Louis van Bloois; Larissa Y Rizzo; Twan Lammers; Rob C Pelger; Gert Storm; Gabri van der Pluijm; Josbert M Metselaar
Journal:  Prostate       Date:  2015-02-08       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.